MindBio Therapeutics Corp. focuses on researching and developing psychedelic substances for mental health treatments. The company faces significant concerns, including a very low current ratio of 0.05, indicating liquidity issues, and an alarming return on assets (ROA) of -2411.5%, suggesting inefficiency in asset utilization. While the market cap is modest at $1.21M, the lack of price movement today may reflect investor caution. Overall, the financial health raises red flags, necessitating careful consideration for potential investors.
Loading financial metrics...
Company has $64K in cash but burned $124K last quarter. At this burn rate, only 0.5 quarters of runway remain without additional financing.
Company posted a loss of $-2.8M over the last year, representing Infinity% of revenue.
Debt of $2.2M is 35.0x the company's cash position of $64K.
Operating cash flow has been negative for 3 consecutive quarters, burning $494K over the last year.
No significant opportunities identified
Based on current financial metrics
Valuation, risk assessment, competitive positioning, and key insights — all in one report.
Other Biotechnology companies of a similar size
Based on 2025-FY (June 30, 2025)